Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Paul Romness Discusses OS Therapies' IPO & Clinical Advancement
MP3•Episode home
Manage episode 436663122 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
OS Therapies CEO Paul Romness joined Steve Darling from Proactive to share news the company has been accepted into Johnson & Johnson Innovation – JLABS, a prestigious platform that supports innovation in the life sciences sector. Through this membership, OS Therapies aims to advance its tunable Antibody Drug Conjugate (ADC) linker-based platform into clinical development. This platform utilizes pH-sensitive linkers and coating technology designed to reduce off-target effects, thereby improving safety and increasing the number and diversity of therapeutic payloads that can be delivered. The tunable ADC platform being developed by OS Therapies holds the promise of offering enhanced efficacy compared to other ADCs currently available or in development. The drug candidates produced using this platform benefit from a unique linker technology, creating new intellectual property for both novel and off-patent targeting antibodies and drug payloads. In addition to this significant milestone, Romness announced that OS Therapies has added Dr. Borys Shor, PhD, to its Antibody Drug Conjugate Advisory Board. Dr. Shor brings over 20 years of experience in oncology discovery programs, particularly in leading preclinical discovery and development efforts for small molecule kinase inhibitors, biologics, and nanoparticles at major pharmaceutical and biotech companies. In his advisory role, Dr. Shor will guide OS Therapies in selecting the most appropriate antibodies and payloads for development using the company's proprietary pH-sensitive SiLinker™ silicone linker technology. These strategic advancements mark a pivotal moment for OS Therapies as it moves closer to bringing innovative and effective cancer therapies to the market. #proactiveinvestors #ostherapies #nyseamerican #ostx #pharma #Immunotherapy #CancerResearch #BiotechIPO #CancerTreatment #Osteosarcoma #BiotechInnovation #PaulRomness #ADCtechnology #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
614 episodes
MP3•Episode home
Manage episode 436663122 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
OS Therapies CEO Paul Romness joined Steve Darling from Proactive to share news the company has been accepted into Johnson & Johnson Innovation – JLABS, a prestigious platform that supports innovation in the life sciences sector. Through this membership, OS Therapies aims to advance its tunable Antibody Drug Conjugate (ADC) linker-based platform into clinical development. This platform utilizes pH-sensitive linkers and coating technology designed to reduce off-target effects, thereby improving safety and increasing the number and diversity of therapeutic payloads that can be delivered. The tunable ADC platform being developed by OS Therapies holds the promise of offering enhanced efficacy compared to other ADCs currently available or in development. The drug candidates produced using this platform benefit from a unique linker technology, creating new intellectual property for both novel and off-patent targeting antibodies and drug payloads. In addition to this significant milestone, Romness announced that OS Therapies has added Dr. Borys Shor, PhD, to its Antibody Drug Conjugate Advisory Board. Dr. Shor brings over 20 years of experience in oncology discovery programs, particularly in leading preclinical discovery and development efforts for small molecule kinase inhibitors, biologics, and nanoparticles at major pharmaceutical and biotech companies. In his advisory role, Dr. Shor will guide OS Therapies in selecting the most appropriate antibodies and payloads for development using the company's proprietary pH-sensitive SiLinker™ silicone linker technology. These strategic advancements mark a pivotal moment for OS Therapies as it moves closer to bringing innovative and effective cancer therapies to the market. #proactiveinvestors #ostherapies #nyseamerican #ostx #pharma #Immunotherapy #CancerResearch #BiotechIPO #CancerTreatment #Osteosarcoma #BiotechInnovation #PaulRomness #ADCtechnology #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
614 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.